4.7 Article

Gut Microbiota Participates in Antithyroid Drug Induced Liver Injury Through the Lipopolysaccharide Related Signaling Pathway

期刊

FRONTIERS IN PHARMACOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.598170

关键词

gut microbiota; antithyroid drugs; lipopolysaccharide; intestinal barrier; liver injury

资金

  1. National Natural Science Foundation of China [81970466]
  2. 2017-2018 Special Fund for Scientific Research Transformation of Heilongjiang Academy of Medical Sciences [CR201803]
  3. Project of scientific research and practical innovation for Postgraduates of Harbin Medical University [YJSKYCX2018-41HYD]

向作者/读者索取更多资源

Background: Drugs can alter the gut microbiota structure, and gut microbiota dysbiosis in turn is correlated with drug side effects through the intestinal endotoxemia hypothesis. Whether antithyroid drugs (including methimazole and propylthiouracil) cause gut microbiota dysbiosis and whether the gut microbiota is correlated with antithyroid drugs induced liver injury is unknown. Methods: Initial Graves' disease patients were randomly divided into the methimazole group (n = 20) and the propylthiouracil group (n = 20) and were followed up every 2 weeks; 50 healthy controls were also included. The structure and function of gut microbiota were compared from the cross sectional and longitudinal levels. The correlation between the gut microbiota and clinical parameters was also determined. In addition, Sprague-Dawley rats were randomly allotted into six groups, including four drug groups, which received daily doses of methimazole (1.5 mg/kg/day; 2.5 mg/kg/day) or propylthiouracil (7.5 mg/kg/day; 12.5 mg/kg/day) by oral gavage, and two control groups received the vehicle. In addition to the indexes mentioned above, intestinal barrier-related indexes were also performed. Results: Cross sectional and longitudinal comparison results from both clinical trials and animal studies indicate that antithyroid drugs altered gut microbiota structure; and the liver function related indexes all increased which correlated with gut microbiota. In addition, lipopolysaccharide-related pathways and the lipopolysaccharide concentration in feces and serum all increased after antithyroid drugs administration. These results consistent with the destroyed intestinal barrier in animal study after antithyroid drugs administration. Conclusion: We verified that antithyroid drugs altered gut microbiota structure and that the gut microbiota may in turn be correlated with antithyroid drugs-induced liver injury through the intestinal endotoxemia hypothesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma

Huinan Chen, Biqiang Zhu, Lei Zhao, Yang Liu, Fuya Zhao, Jing Feng, Ye Jin, Jiayu Sun, Rui Geng, Yunwei Wei

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)

Article Microbiology

Gut microbiota in patients after surgical treatment for colorectal cancer

Ye Jin, Yang Liu, Lei Zhao, Fuya Zhao, Jing Feng, Shengda Li, Huinan Chen, Jiayu Sun, Biqiang Zhu, Rui Geng, Yunwei Wei

ENVIRONMENTAL MICROBIOLOGY (2019)

Article Oncology

Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients

Jing Feng, Fuya Zhao, Jiayu Sun, Baiqiang Lin, Lei Zhao, Yang Liu, Ye Jin, Shengda Li, Aidong Li, Yunwei Wei

INTERNATIONAL JOURNAL OF CANCER (2019)

Article Biochemistry & Molecular Biology

Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma

Biqiang Zhu, Lei Zhao, Yang Liu, Ye Jin, Jing Feng, Fuya Zhao, Jiayu Sun, Rui Geng, Yunwei Wei

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)

Article Oncology

Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma

Lei Zhao, Yang Liu, Fuya Zhao, Ye Jin, Jing Feng, Rui Geng, Jiayu Sun, Liqing Kang, Lei Yu, Yunwei Wei

MOLECULAR THERAPY-ONCOLYTICS (2020)

暂无数据